Extrawell Pharmaceutical Holdings Limited

SEHK:858 Rapporto sulle azioni

Cap. di mercato: HK$126.7m

Extrawell Pharmaceutical Holdings Gestione

Gestione criteri di controllo 3/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Yi Xie

Amministratore delegato

HK$1.4m

Compenso totale

Percentuale dello stipendio del CEO94.9%
Mandato del CEO10.9yrs
Proprietà del CEOn/a
Durata media del managementNessun dato
Durata media del Consiglio di amministrazione13.5yrs

Aggiornamenti recenti sulla gestione

Recent updates

Here's Why Extrawell Pharmaceutical Holdings (HKG:858) Can Afford Some Debt

Mar 18
Here's Why Extrawell Pharmaceutical Holdings (HKG:858) Can Afford Some Debt

Extrawell Pharmaceutical Holdings (HKG:858) Is Making Moderate Use Of Debt

Dec 01
Extrawell Pharmaceutical Holdings (HKG:858) Is Making Moderate Use Of Debt

We Think That There Are Some Issues For Extrawell Pharmaceutical Holdings (HKG:858) Beyond Its Promising Earnings

Aug 04
We Think That There Are Some Issues For Extrawell Pharmaceutical Holdings (HKG:858) Beyond Its Promising Earnings

Is Extrawell Pharmaceutical Holdings (HKG:858) Using Debt Sensibly?

Mar 15
Is Extrawell Pharmaceutical Holdings (HKG:858) Using Debt Sensibly?

Some Shareholders May Object To A Pay Rise For Extrawell Pharmaceutical Holdings Limited's (HKG:858) CEO This Year

Aug 20
Some Shareholders May Object To A Pay Rise For Extrawell Pharmaceutical Holdings Limited's (HKG:858) CEO This Year

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Yi Xie rispetto agli utili di Extrawell Pharmaceutical Holdings?
DataCompenso totaleStipendioGuadagni aziendali
Mar 31 2024HK$1mHK$1m

-HK$163m

Dec 31 2023n/an/a

-HK$159m

Sep 30 2023n/an/a

-HK$154m

Jun 30 2023n/an/a

-HK$13m

Mar 31 2023HK$1mHK$1m

HK$129m

Dec 31 2022n/an/a

HK$109m

Sep 30 2022n/an/a

HK$88m

Jun 30 2022n/an/a

HK$109m

Mar 31 2022HK$1mHK$1m

HK$131m

Dec 31 2021n/an/a

HK$12m

Sep 30 2021n/an/a

-HK$107m

Jun 30 2021n/an/a

-HK$114m

Mar 31 2021HK$1mHK$1m

-HK$121m

Dec 31 2020n/an/a

HK$6m

Sep 30 2020n/an/a

HK$133m

Jun 30 2020n/an/a

HK$108m

Mar 31 2020HK$1mHK$1m

HK$83m

Dec 31 2019n/an/a

HK$73m

Sep 30 2019n/an/a

HK$63m

Jun 30 2019n/an/a

HK$63m

Mar 31 2019HK$1mHK$1m

HK$64m

Dec 31 2018n/an/a

HK$51m

Sep 30 2018n/an/a

HK$39m

Jun 30 2018n/an/a

HK$34m

Mar 31 2018HK$1mHK$1m

HK$30m

Compensazione vs Mercato: La retribuzione totale di Yi ($USD 178.11K ) è circa la media per le aziende di dimensioni simili nel mercato Hong Kong ($USD 232.99K ).

Compensazione vs guadagni: La retribuzione di Yi è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Yi Xie (61 yo)

10.9yrs

Mandato

HK$1,386,000

Compensazione

Dr. Yi Xie, Ph.D. serves as the Chief Executive Officer of Extrawell Pharmaceutical Holdings Ltd. Dr. Xie is one of the founders of United Gene group of companies in the PRC. Dr. Xie is responsible for res...

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Yi Xie
Executive Chairman & CEO10.9yrsHK$1.39mNessun dato
Yi Lou
Executive Director16.1yrsHK$557.00kNessun dato
Yong Cheng
Deputy CEO & Executive Director10.9yrsHK$713.00k6.14%
HK$ 7.8m
Yi Guo
Executive Director1.6yrsNessun datoNessun dato
Sau Kuen Wong
Company Secretary & Executive Director16.1yrsHK$940.00kNessun dato
Yumin Mao
Honorary Chairman and Chief Scientific Advisorno dataNessun dato7.95%
HK$ 10.1m
Lin Hu Fang
Independent Non-Executive Director23.8yrsHK$70.00kNessun dato
Song Jin
Independent Non-Executive Director20.2yrsHK$70.00kNessun dato
Li Zeng
Independent Non-Executive Directorless than a yearNessun datoNessun dato

13.5yrs

Durata media

61yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di 858 è composto da personale esperto e esperto (durata media dell'incarico 13.5 anni).